Lobbying registration dated 2026-02-23
Registrant: Victor Neagu
Client: Eli Lilly Canada Inc.
Targeted institutions:
Finance Canada (FIN)
Treasury Board Of Canada Secretariat (TBS)
Agriculture and Agri-Food Canada (AAFC)
Prime Minister's Office (PMO)
House of Commons
Great Lakes Pilotage Authority
Innovation, Science and Economic Development Canada (ISED)
Invest in Canada Hub
Global Affairs Canada (GAC)
Public Health Agency of Canada (PHAC)
Patented Medicine Prices Review Board (PMPRB)
Federal Economic Development Agency for Southern Ontario (FedDev)
Privy Council Office (PCO)
Senate of Canada
Health Canada (HC)
Legislative bills: C-64
Acts: Patent Act
Government funding received:
Lobbying activity details:
Patented Medicines Pricing Review Board (PMPRB) – regulations that can impact the Canadian pharmaceutical industry.
Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly's business.
Free trade treaty agreement as it relates to the Canada/US Free Trade Agreement and free trade negotiations as it relates to Columbia, India, and the European Union.
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
C-64, An act respecting pharmacare - discussions around the structuring and implementation of a national pharmacare program.
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry.
Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.
Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food & Drug Act.